I 119th CONGRESS 1st Session H. R. 1796 IN THE HOUSE OF REPRESENTATIVES March 3, 2025 Mr. James (for himself, Mr. Veasey , Mr. Carter of Louisiana , Mr. Davis of Illinois , and Mrs. Kiggans of Virginia ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program. 1. Short title This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025”. 2. Sickle cell disease treatment prevention and treatment (a) In general Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended— (1) in paragraph (1)(A)(iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; (2) in paragraph (2)(D), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; (3) in paragraph (3)— (A) in subparagraph (A), by striking “enter into a contract with” and inserting “make a grant to, or enter into a contract or cooperative agreement with,”; and (B) in subparagraph (B), in each of clauses (ii) and (iii), by striking “prevention and treatment of sickle cell disease” and inserting “treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease”; and (4) in paragraph (6), by striking “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2025 through 2029”. (b) Sense of Congress It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.